

Ibuprofen and morphine for acute pain in sickle cell disease

Submission date 03/04/2009	Recruitment status Stopped	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 08/04/2009	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 13/06/2016	Condition category Haematological Disorders	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=92

Contact information

Type(s)

Scientific

Contact name

Dr Kofi Anie

Contact details

Haematology and Sickle Cell Centre
North West London Hospitals NHS Trust
Central Middlesex Hospital
Acton Lane
London
United Kingdom
NW10 7NS
+44 (0)20 8453 2050
Kofi.Anie@nwlh.nhs.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00880373

Protocol serial number

HTA 07/48/01

Study information

Scientific Title

An evaluation of the effectiveness of ibuprofen and morphine for acute pain in sickle cell disease: a double-blind, placebo-controlled randomised trial

Acronym

SWIM (Sickle With Ibuprofen and Morphine)

Study objectives

The use of oral ibuprofen combined with morphine administered through patient controlled analgesia (PCA) will be clinically effective for acute pain crisis in adults with sickle cell disease (SCD).

More details can be found at: <http://www.hta.ac.uk/1782>

Protocol can be found at: <http://www.hta.ac.uk/protocols/200700480001.pdf>

Ethics approval required

Old ethics approval format

Ethics approval(s)

London Research Ethics Committee, 27/02/2009, ref: 08/H0718/79

Study design

Double-blind placebo-controlled randomised trial

Primary study design

Interventional

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Sickle cell disease

Interventions

Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days. There will be a matching placebo for each active drug. Participants will be randomly allocated to one of two treatment groups:

1. Morphine by PCA and oral ibuprofen
2. Morphine by PCA and oral placebo

Follow-up is at 1 week and 4 weeks post-discharge for both treatment groups.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Ibuprofen, morphine

Primary outcome(s)

PCA morphine consumption over 4 days

Key secondary outcome(s)

1. Rapidity of pain control - time to achieve a pain score of 4 on a standard 10-point numeric rating scale within 4 days (based on assessments of patients attending Central Middlesex Hospital)
2. Mood - measured on the Hospital Anxiety and Depression Scale (HADS)
3. Adverse opioid effects - including nausea, constipation, itching, and central nervous system effects
4. Other sickle cell complications - including neurological events, and acute chest syndrome
5. Use of blood transfusions - treatment for complications during or post-discharge study period of 4 weeks
6. Health service utilisation cost - length of hospital admission, and re-admission in 7 - 14 days
7. Quality of life and utility - measured on the EuroQol (EQ-5D)
8. Patient satisfaction - patient experience at discharge

Completion date

31/08/2013

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility**Key inclusion criteria**

Adult patients with SCD of any phenotype and gender aged 16 years and over.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

16 years

Sex

All

Key exclusion criteria

1. Patient has a history of allergic reaction to either morphine or ibuprofen
2. Patient has contraindications to morphine or ibuprofen, e.g. peptic ulcer disease, non-steroidal anti-inflammatory drug (NSAID)-induced asthma
3. Patient in a drug dependency programme
4. Patient is on renal dialysis
5. Stroke within the last 6 weeks

6. Platelet count less than $50 \times 10^9/l$
7. Patient is pregnant or breastfeeding
8. Doctor unwilling to randomise the patient for other reasons
9. Previous participation in the trial

Date of first enrolment

01/09/2009

Date of final enrolment

31/08/2013

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

North West London Hospitals NHS Trust

London

United Kingdom

NW10 7NS

Sponsor information

Organisation

North West London Hospitals NHS Trust (UK)

ROR

<https://ror.org/04cntmc13>

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Other publications	why trial was stopped:	09/06/2016		Yes	No